What We have Learned about Pain from Rodent Models of Arthritis?

被引:0
|
作者
Inglis, Julia J. [1 ,2 ]
Schutze, Mark U. [3 ]
McNamee, Kay E. [4 ]
机构
[1] Murdoch Univ, Sch Vet & Biomed Sci, Perth, WA, Australia
[2] Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA, Australia
[3] Sir Charles Gairdner Hosp, Dept Pain Management, Perth, WA, Australia
[4] Imperial Coll London, London W6 8LH, England
关键词
Pain mechanisms; animal models; rodent; osteoarthritis; rheumatoid arthritis; analgesics;
D O I
10.2174/157339710791792748
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rheumatoid arthritis (RA) and Osteoarthritis (OA) are both common diseases of the joints. RA is distinguished by inflammation and synovitis leading to joint destruction, whereas OA is typified by degenerative and mostly noninflammatory disease. Although differing in their pathology, both forms can elicit chronic disabling pain in patients. Relief from this pain is an unmet need for many patients, and this has lead to a drive to understand the pain mechanisms occurring in each disease in order to develop new analgesics. This necessitates the use of pre-clinical models. Here we discuss the methods and limitations of animal pain assessment, rodent models of RA and OA, and how these models have been used to investigate the genesis of pain. Specifically, we focus on processes studied in both RA and OA models, and how the mediators involved in the development of pain may differ between these two arthritic states and during acute and chronic pain. From this we have learnt that the key mediators of RA pain include inflammatory cells, inflammatory cytokines, astrocytes, substance P, and CGRP. Endogenous analgesic mediators in RA include beta-endorphin, mu-opioid receptor, and various anti-inflammatory cytokines. Less is known of the mediators of OA pain, but important factors include CGRP, TRPV1, NGF, VIP and the mu-opioid receptor. Interestingly, several factors have been found not to play a role in OA pain, including glial cells, neutrophils and TNF. It must be noted that the vast majority of candidate drugs from animal research never reach the human clinic, in part due to false positives from animal models. This may be due to flaws in the models themselves, the methods used to assess pain, the physical properties of the candidate drug, or an inherent difference between animal and human pain pathways. By developing more clinically relevant models, novel diseasespecific analgesics are being developed with the hope of improving the quality of life for sufferers of arthritis pain.
引用
收藏
页码:194 / 207
页数:14
相关论文
共 50 条
  • [1] Animal models of arthritis. What have we learned?
    van den Berg, WB
    JOURNAL OF RHEUMATOLOGY, 2005, 32 : 7 - 9
  • [2] Rheumatoid arthritis: What have we learned about the causing factors?
    Jalil, Syed Fazal
    Arshad, Maria
    Bhatti, Attya
    Ahmad, Jamil
    Akbar, Fazal
    Ali, Shahid
    John, Peter
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 29 (02) : 629 - 645
  • [3] Periodontitis and rheumatoid arthritis: What have we learned about their connection and their treatment?
    Gonzalez-Febles, Jerian
    Sanz, Mariano
    PERIODONTOLOGY 2000, 2021, 87 (01) : 181 - 203
  • [4] Genetics of rheumatoid arthritis: what have we learned?
    Marieke Bax
    Jurgen van Heemst
    Tom W. J. Huizinga
    Rene E. M. Toes
    Immunogenetics, 2011, 63 : 459 - 466
  • [5] Genetics of rheumatoid arthritis: what have we learned?
    Bax, Marieke
    van Heemst, Jurgen
    Huizinga, Tom W. J.
    Toes, Rene E. M.
    IMMUNOGENETICS, 2011, 63 (08) : 459 - 466
  • [6] Cardiovascular imaging: what have we learned from animal models?
    Santos, Arnoldo
    Fernandez-Friera, Leticia
    Villalba, Maria
    Lopez-Melgar, Beatriz
    Espana, Samuel
    Mateo, Jesus
    Mota, Ruben A.
    Jimenez-Borreguero, Jesus
    Ruiz-Cabello, Jesus
    FRONTIERS IN PHARMACOLOGY, 2015, 6
  • [7] Hyperoxia and Lungs: What We Have Learned From Animal Models
    Amarelle, Luciano
    Quintela, Lucia
    Hurtado, Javier
    Malacrida, Leonel
    FRONTIERS IN MEDICINE, 2021, 8
  • [8] What have we learned recently from transgenic mouse models about neurodegeneration? The most promising discoveries of this millennium
    Kreiner, Grzegorz
    PHARMACOLOGICAL REPORTS, 2018, 70 (06) : 1105 - 1115
  • [9] Animal models of the ketogenic diet: what have we learned, what can we learn?
    Stafstrom, CE
    EPILEPSY RESEARCH, 1999, 37 (03) : 241 - 259
  • [10] Tomatoes, Lycopene, and Prostate Cancer: What Have We Learned from Experimental Models?
    Moran, Nancy E.
    Thomas-Ahner, Jennifer M.
    Wan, Lei
    Zuniga, Krystle E.
    Erdman, John W.
    Clinton, Steven K.
    JOURNAL OF NUTRITION, 2022, 152 (06) : 1381 - 1403